<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ACR 2025 Vasculitis Highlights</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #1a3a5c 0%, #2d5a8a 100%);
            min-height: 100vh;
            color: #333;
        }
        .header {
            background: #1a3a5c;
            color: white;
            padding: 30px 20px;
            text-align: center;
            border-bottom: 4px solid #c41e3a;
        }
        .header h1 {
            font-size: 28px;
            margin-bottom: 8px;
        }
        .header p {
            color: #a8c4e0;
            font-size: 14px;
        }
        .container {
            max-width: 900px;
            margin: 0 auto;
            padding: 20px;
        }
        .section {
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            overflow: hidden;
            box-shadow: 0 4px 15px rgba(0,0,0,0.2);
        }
        .section-header {
            background: #c41e3a;
            color: white;
            padding: 15px 20px;
            font-size: 18px;
            font-weight: 600;
        }
        .section-header.navy {
            background: #1a3a5c;
        }
        .abstract-list {
            padding: 0;
        }
        .abstract-item {
            padding: 15px 20px;
            border-bottom: 1px solid #eee;
            display: block;
            text-decoration: none;
            color: #333;
            transition: background 0.2s;
        }
        .abstract-item:hover {
            background: #f5f8fa;
        }
        .abstract-item:last-child {
            border-bottom: none;
        }
        .abstract-number {
            display: inline-block;
            background: #1a3a5c;
            color: white;
            padding: 2px 8px;
            border-radius: 4px;
            font-size: 12px;
            margin-right: 10px;
        }
        .abstract-title {
            font-weight: 500;
            color: #1a3a5c;
            line-height: 1.4;
        }
        .abstract-category {
            font-size: 12px;
            color: #888;
            margin-top: 5px;
        }
        .highlight-badge {
            display: inline-block;
            background: #c41e3a;
            color: white;
            padding: 2px 8px;
            border-radius: 4px;
            font-size: 11px;
            margin-left: 8px;
        }
        .news-item {
            padding: 15px 20px;
            border-bottom: 1px solid #eee;
            display: block;
            text-decoration: none;
            color: #333;
            transition: background 0.2s;
        }
        .news-item:hover {
            background: #f5f8fa;
        }
        .news-item:last-child {
            border-bottom: none;
        }
        .news-source {
            font-size: 12px;
            color: #c41e3a;
            font-weight: 600;
            margin-bottom: 5px;
        }
        .news-title {
            font-weight: 500;
            color: #1a3a5c;
            line-height: 1.4;
        }
        .footer {
            text-align: center;
            padding: 30px 20px;
            color: #a8c4e0;
            font-size: 14px;
        }
        .footer a {
            color: #e85a70;
        }
        .drug-tag {
            display: inline-block;
            background: #e8f4e8;
            color: #2d6a2d;
            padding: 2px 8px;
            border-radius: 4px;
            font-size: 11px;
            margin-left: 8px;
        }
        .drug-tag.jak {
            background: #fff0f0;
            color: #c41e3a;
        }
        .drug-tag.il5 {
            background: #f0f0ff;
            color: #4a4ac4;
        }
        .drug-tag.c5a {
            background: #fff8e8;
            color: #8a6a2d;
        }
        .intro-box {
            background: #f5f8fa;
            padding: 20px;
            margin: 20px;
            border-radius: 8px;
            border-left: 4px solid #c41e3a;
        }
        .intro-box h3 {
            color: #1a3a5c;
            margin-bottom: 10px;
        }
        .intro-box p {
            color: #5a7a9a;
            font-size: 14px;
            line-height: 1.5;
        }
    </style>
</head>
<body>
    <div class="header">
        <h1>ACR Convergence 2025</h1>
        <p>Vasculitis Highlights & Resources</p>
        <p style="margin-top: 8px; color: #e85a70;">Chicago, IL â€¢ October 24-29, 2025</p>
    </div>

    <div class="container">
        <div class="section">
            <div class="intro-box">
                <h3>Welcome!</h3>
                <p>This page contains links to the top vasculitis abstracts from ACR 2025 plus news coverage and social media discussions. Click any item to view the full abstract or article.</p>
            </div>
        </div>

        <!-- TOP HIGHLIGHTS -->
        <div class="section">
            <div class="section-header">ðŸ”¥ Most Talked-About Abstracts</div>
            <div class="abstract-list">
                <a href="https://acrabstracts.org/abstract/impact-of-glucocorticoid-tapering-in-giant-cell-arteritis-analysis-from-the-select-gca-trial/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#0895</span>
                    <span class="abstract-title">Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial</span>
                    <span class="highlight-badge">TOP PICK</span>
                    <span class="drug-tag jak">Upadacitinib</span>
                    <div class="abstract-category">GCA â€¢ SELECT-GCA Trial â€¢ FDA Approved April 2025</div>
                </a>
                <a href="https://acrabstracts.org/abstract/methotrexate-versus-tocilizumab-for-treatment-of-giant-cell-arteritis-metogia-trial-a-multicenter-randomized-controlled-trial/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#0891</span>
                    <span class="abstract-title">MEthotrexate versus TOcilizumab for Treatment of Giant Cell Arteritis (METOGiA Trial)</span>
                    <span class="highlight-badge">ORAL</span>
                    <div class="abstract-category">GCA â€¢ Head-to-head comparison</div>
                </a>
                <a href="https://acrabstracts.org/abstract/mepolizumab-to-benralizumab-switch-in-eosinophilic-granulomatosis-with-polyangiitis-egpa/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#1592</span>
                    <span class="abstract-title">Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)</span>
                    <span class="drug-tag il5">Anti-IL5</span>
                    <div class="abstract-category">EGPA â€¢ MANDARA Trial Follow-up</div>
                </a>
                <a href="https://acrabstracts.org/abstract/real-world-clinical-effectiveness-of-benralizumab-for-eosinophilic-granulomatosis-with-polyangiitis-a-national-multicenter-study/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#1600</span>
                    <span class="abstract-title">Real-world Clinical Effectiveness of Benralizumab for EGPA: A National Multicenter Study</span>
                    <span class="drug-tag il5">Benralizumab</span>
                    <div class="abstract-category">EGPA â€¢ Real-world data</div>
                </a>
                <a href="https://acrabstracts.org/abstract/real-world-avacopan-use-in-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-insights-from-united-states-claims-data/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#0726</span>
                    <span class="abstract-title">Real-World Avacopan Use in GPA and MPA: Insights from United States Claims Data</span>
                    <span class="drug-tag c5a">Avacopan</span>
                    <div class="abstract-category">AAV â€¢ Real-world outcomes</div>
                </a>
            </div>
        </div>

        <!-- GCA & LARGE VESSEL -->
        <div class="section">
            <div class="section-header navy">Giant Cell Arteritis & Large Vessel Vasculitis</div>
            <div class="abstract-list">
                <a href="https://acrabstracts.org/abstract/relapse-and-immune-dysregulation-in-giant-cell-arteritis-are-linked-to-mosaic-loss-of-the-y-chromosome/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#0892</span>
                    <span class="abstract-title">Relapse and Immune Dysregulation in GCA Linked to Mosaic Loss of the Y Chromosome</span>
                    <span class="highlight-badge">NOVEL</span>
                    <div class="abstract-category">GCA â€¢ Basic Science</div>
                </a>
                <a href="https://acrabstracts.org/abstract/effectiveness-and-safety-of-janus-kinase-inhibitors-in-giant-cell-arteritis-real-world-clinical-practice-study/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#0737</span>
                    <span class="abstract-title">Effectiveness and Safety of JAK Inhibitors in Giant Cell Arteritis: Real-World Study</span>
                    <span class="drug-tag jak">JAKi</span>
                    <div class="abstract-category">GCA â€¢ Real-world JAKi data</div>
                </a>
                <a href="https://acrabstracts.org/abstract/fast-track-clinics-improve-visual-outcomes-in-giant-cell-arteritis-a-meta-analysis/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#0761</span>
                    <span class="abstract-title">Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis</span>
                    <div class="abstract-category">GCA â€¢ Clinical Practice</div>
                </a>
                <a href="https://acrabstracts.org/abstract/use-of-jak-inhibitors-in-patients-with-refractory-takayasu-arteritis-a-worldwide-retrospective-study/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#1618</span>
                    <span class="abstract-title">JAK Inhibitors in Refractory Takayasu Arteritis: A Worldwide Retrospective Study</span>
                    <span class="drug-tag jak">JAKi</span>
                    <div class="abstract-category">Takayasu â€¢ Global data</div>
                </a>
                <a href="https://acrabstracts.org/abstract/diagnostic-performance-of-vascular-ultrasound-in-giant-cell-arteritis/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#2702</span>
                    <span class="abstract-title">Diagnostic Performance of Vascular Ultrasound in Giant Cell Arteritis</span>
                    <div class="abstract-category">GCA â€¢ Imaging â€¢ Great Debate topic</div>
                </a>
            </div>
        </div>

        <!-- ANCA-ASSOCIATED -->
        <div class="section">
            <div class="section-header">ANCA-Associated Vasculitis</div>
            <div class="abstract-list">
                <a href="https://acrabstracts.org/abstract/risk-of-drug-induced-liver-injury-with-use-of-avacopan-in-anca-vasculitis-results-from-real-world-data/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#0724</span>
                    <span class="abstract-title">Risk of Drug Induced Liver Injury with Avacopan in ANCA Vasculitis: Real-World Data</span>
                    <span class="drug-tag c5a">Avacopan</span>
                    <div class="abstract-category">AAV â€¢ Safety</div>
                </a>
                <a href="https://acrabstracts.org/abstract/maintenance-of-remission-with-rituximab-versus-azathioprine-in-eosinophilic-granulomatosis-with-polyangiitis/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#1765</span>
                    <span class="abstract-title">Maintenance with Rituximab vs Azathioprine in EGPA: Randomized Controlled Trial</span>
                    <span class="highlight-badge">ORAL</span>
                    <div class="abstract-category">EGPA â€¢ RCT</div>
                </a>
                <a href="https://acrabstracts.org/abstract/obinutuzumab-induces-and-maintains-remission-in-refractory-anca-associated-vasculitis/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#1601</span>
                    <span class="abstract-title">Obinutuzumab Induces and Maintains Remission in Refractory ANCA-Associated Vasculitis</span>
                    <span class="highlight-badge">NOVEL</span>
                    <div class="abstract-category">AAV â€¢ Refractory disease</div>
                </a>
                <a href="https://acrabstracts.org/abstract/sglt-2-inhibitors-are-associated-with-lower-risk-of-esrd-and-mortality-in-anca-vasculitis/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#1603</span>
                    <span class="abstract-title">SGLT-2 Inhibitors Associated with Lower ESRD and Mortality Risk in AAV</span>
                    <span class="highlight-badge">NOVEL</span>
                    <div class="abstract-category">AAV â€¢ Renal protection</div>
                </a>
                <a href="https://acrabstracts.org/abstract/avacopan-is-not-associated-with-an-increased-risk-of-infection-compared-to-glucocorticoids/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#2505</span>
                    <span class="abstract-title">Avacopan Not Associated With Increased Infection Risk vs Glucocorticoids</span>
                    <span class="drug-tag c5a">Avacopan</span>
                    <div class="abstract-category">AAV â€¢ Safety</div>
                </a>
                <a href="https://acrabstracts.org/abstract/early-mepolizumab-initiation-enables-high-glucocorticoid-discontinuation-rates-in-egpa/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#1610</span>
                    <span class="abstract-title">Early Mepolizumab Enables High Glucocorticoid Discontinuation Rates in EGPA</span>
                    <span class="drug-tag il5">Mepolizumab</span>
                    <div class="abstract-category">EGPA â€¢ Steroid-sparing</div>
                </a>
            </div>
        </div>

        <!-- IgG4-RD & OTHER -->
        <div class="section">
            <div class="section-header navy">IgG4-Related Disease & Other Vasculitides</div>
            <div class="abstract-list">
                <a href="https://acrabstracts.org/abstract/broad-screening-of-the-human-proteome-identifies-a-cassette-of-six-autoantigens-that-distinguishes-igg4-related-disease/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#2528</span>
                    <span class="abstract-title">Six-Autoantigen Cassette That Distinguishes IgG4-Related Disease</span>
                    <span class="highlight-badge">BIOMARKER</span>
                    <div class="abstract-category">IgG4-RD â€¢ Diagnostic</div>
                </a>
                <a href="https://acrabstracts.org/abstract/broad-screening-of-inflammation-associated-proteins-identifies-serum-ccl19-and-ccl2-as-biomarkers-in-igg4-related-disease/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#2530</span>
                    <span class="abstract-title">Serum CCL19 and CCL2 as Biomarkers of Disease Activity in IgG4-RD</span>
                    <span class="highlight-badge">BIOMARKER</span>
                    <div class="abstract-category">IgG4-RD â€¢ Activity monitoring</div>
                </a>
                <a href="https://acrabstracts.org/abstract/coronary-periarteritis-in-igg4-related-disease/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#2531</span>
                    <span class="abstract-title">Coronary Periarteritis in IgG4-Related Disease</span>
                    <div class="abstract-category">IgG4-RD â€¢ Cardiac</div>
                </a>
                <a href="https://acrabstracts.org/abstract/neutrophil-transcriptomics-and-maturation-pathways-in-vexas-syndrome/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#2700</span>
                    <span class="abstract-title">Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome</span>
                    <span class="highlight-badge">ORAL</span>
                    <div class="abstract-category">VEXAS â€¢ Basic science</div>
                </a>
                <a href="https://acrabstracts.org/abstract/cutaneous-iga-vasculitis-emulation-of-a-target-trial/" class="abstract-item" target="_blank">
                    <span class="abstract-number">#2699</span>
                    <span class="abstract-title">Cutaneous IgA Vasculitis: Emulation of a Target Trial</span>
                    <span class="highlight-badge">ORAL</span>
                    <div class="abstract-category">IgA Vasculitis â€¢ Treatment</div>
                </a>
            </div>
        </div>

        <!-- NEWS & COVERAGE -->
        <div class="section">
            <div class="section-header">ðŸ“° News Coverage & Expert Commentary</div>
            <div class="abstract-list">
                <a href="https://www.the-rheumatologist.org/article/advances-in-gca/" class="news-item" target="_blank">
                    <div class="news-source">The Rheumatologist</div>
                    <div class="news-title">Advances in Giant Cell Arteritis: SELECT-GCA and Beyond</div>
                </a>
                <a href="https://www.the-rheumatologist.org/article/fda-approves-upadacitinib-for-gca/" class="news-item" target="_blank">
                    <div class="news-source">The Rheumatologist</div>
                    <div class="news-title">FDA Approves Upadacitinib for Giant Cell Arteritis</div>
                </a>
                <a href="https://www.the-rheumatologist.org/article/the-great-debate-ultrasound-vs-temporal-artery-biopsy-in-giant-cell-arteritis/" class="news-item" target="_blank">
                    <div class="news-source">The Rheumatologist</div>
                    <div class="news-title">Great Debate: Ultrasound vs Temporal Artery Biopsy in GCA</div>
                </a>
                <a href="https://www.healio.com/news/rheumatology/20251024/all-in-one-place-healio-rheumatology-peer-board-previews-acr-convergence-2025" class="news-item" target="_blank">
                    <div class="news-source">Healio Rheumatology</div>
                    <div class="news-title">ACR Convergence 2025 Preview: What to Watch in Vasculitis</div>
                </a>
                <a href="https://rheumnow.com/conference/acr-2025" class="news-item" target="_blank">
                    <div class="news-source">RheumNow</div>
                    <div class="news-title">ACR 2025 Conference Coverage Hub</div>
                </a>
                <a href="https://rheumnow.com/news/2025-bsr-recommendations-anca-associated-vasculitis" class="news-item" target="_blank">
                    <div class="news-source">RheumNow</div>
                    <div class="news-title">2025 BSR Recommendations for ANCA-Associated Vasculitis</div>
                </a>
                <a href="https://rheumnow.com/news/2025-acr-guidance-diagnosis-and-management-vexas" class="news-item" target="_blank">
                    <div class="news-source">RheumNow</div>
                    <div class="news-title">2025 ACR Guidance on Diagnosis and Management of VEXAS</div>
                </a>
                <a href="https://igg4ward.org/igg4ward-educational-resources/acr-convergence-2025-manage-hope-thrive/" class="news-item" target="_blank">
                    <div class="news-source">IgG4ward Foundation</div>
                    <div class="news-title">IgG4-RD at ACR Convergence 2025: Manage, Hope, Thrive</div>
                </a>
                <a href="https://www.emjreviews.com/rheumatology/congress-review/review-of-the-american-college-of-rheumatology-acr-convergence-2025-j170125/" class="news-item" target="_blank">
                    <div class="news-source">EMJ Reviews</div>
                    <div class="news-title">Review of ACR Convergence 2025</div>
                </a>
            </div>
        </div>

        <!-- KEY TRIALS -->
        <div class="section">
            <div class="section-header navy">ðŸ“š Key Trial Publications</div>
            <div class="abstract-list">
                <a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2413449" class="news-item" target="_blank">
                    <div class="news-source">NEJM</div>
                    <div class="news-title">SELECT-GCA: Upadacitinib Phase 3 Trial in Giant Cell Arteritis</div>
                </a>
                <a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2311155" class="news-item" target="_blank">
                    <div class="news-source">NEJM</div>
                    <div class="news-title">MANDARA Trial: Benralizumab vs Mepolizumab for EGPA</div>
                </a>
            </div>
        </div>

    </div>

    <div class="footer">
        <p>Compiled by Ali Bays, MD</p>
        <p style="margin-top: 8px;">ACR Convergence 2025 â€¢ Chicago, IL</p>
        <p style="margin-top: 15px; font-size: 12px;">
            Full abstracts available at <a href="https://acrabstracts.org/meetings/acr-convergence-2025/" target="_blank">acrabstracts.org</a>
        </p>
    </div>
</body>
</html>
